Posttransplant Cyclophosphamide and Antithymocyte Globulin versus Posttransplant Cyclophosphamide as Graft-versus-Host Disease Prophylaxis for Peripheral Blood Stem Cell Haploidentical Transplants: Comparison of T Cell and NK Effector Reconstitution.


Journal

Journal of immunology (Baltimore, Md. : 1950)
ISSN: 1550-6606
Titre abrégé: J Immunol
Pays: United States
ID NLM: 2985117R

Informations de publication

Date de publication:
01 09 2020
Historique:
received: 19 05 2020
accepted: 04 07 2020
pubmed: 5 8 2020
medline: 23 3 2021
entrez: 5 8 2020
Statut: ppublish

Résumé

A higher incidence of graft-versus-host disease (GVHD) has been observed after haploidentical hematopoietic stem cell transplantation (h-HSCT) with posttransplant cyclophosphamide (PTCY) using peripheral blood stem cells (PBSC) as a source of graft. Moreover, combining PTCY with antithymocyte globulin (ATG) may help to reduce GVHD incidence. In this study, early immune reconstitution, especially of T and NK cell compartments, was compared after both types of transplant (PTCY versus PTCY + ATG) investigate their influence on patient outcomes. This retrospective study included 58 adults who received a reduced intensity conditioning to PBSC h-HSCT with cyclosporine and mycophenolate mofetyl + PTCY (

Identifiants

pubmed: 32747504
pii: jimmunol.2000578
doi: 10.4049/jimmunol.2000578
doi:

Substances chimiques

Antilymphocyte Serum 0
CD3 Complex 0
Immunosuppressive Agents 0
Cyclophosphamide 8N3DW7272P

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1441-1448

Informations de copyright

Copyright © 2020 by The American Association of Immunologists, Inc.

Auteurs

Dhon Roméo Makanga (DR)

Etablissement Français du Sang, Centre-Pays de la Loire, 44011 Nantes, France.
Université de Nantes, CNRS, INSERM, Centre de Recherche en Cancérologie et Immunologie Nantes-Angers, 44000 Nantes, France.
Laboratoire d'Excellence Immunotherapy Graft Oncology, 44000 Nantes, France.

Thierry Guillaume (T)

Université de Nantes, CNRS, INSERM, Centre de Recherche en Cancérologie et Immunologie Nantes-Angers, 44000 Nantes, France.
Laboratoire d'Excellence Immunotherapy Graft Oncology, 44000 Nantes, France.

Catherine Willem (C)

Etablissement Français du Sang, Centre-Pays de la Loire, 44011 Nantes, France.
Université de Nantes, CNRS, INSERM, Centre de Recherche en Cancérologie et Immunologie Nantes-Angers, 44000 Nantes, France.
Laboratoire d'Excellence Immunotherapy Graft Oncology, 44000 Nantes, France.

Nolwenn Legrand (N)

Etablissement Français du Sang, Centre-Pays de la Loire, 44011 Nantes, France.
Université de Nantes, CNRS, INSERM, Centre de Recherche en Cancérologie et Immunologie Nantes-Angers, 44000 Nantes, France.
Laboratoire d'Excellence Immunotherapy Graft Oncology, 44000 Nantes, France.

Katia Gagne (K)

Etablissement Français du Sang, Centre-Pays de la Loire, 44011 Nantes, France.
Université de Nantes, CNRS, INSERM, Centre de Recherche en Cancérologie et Immunologie Nantes-Angers, 44000 Nantes, France.
Laboratoire d'Excellence Immunotherapy Graft Oncology, 44000 Nantes, France.
LabEx Transplantex, Université de Strasbourg, 67000 Strasbourg, France.

Anne Cesbron (A)

Etablissement Français du Sang, Centre-Pays de la Loire, 44011 Nantes, France.
LabEx Transplantex, Université de Strasbourg, 67000 Strasbourg, France.

Ketevan Gendzekhadze (K)

Histocompatibility Laboratory, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA 91010.

Pierre Peterlin (P)

Hematology Clinic, Centre Hopitalier-Universitaire, 44000 Nantes, France; and.

Alice Garnier (A)

Hematology Clinic, Centre Hopitalier-Universitaire, 44000 Nantes, France; and.

Amandine Le Bourgeois (A)

Hematology Clinic, Centre Hopitalier-Universitaire, 44000 Nantes, France; and.

Marie C Béné (MC)

Université de Nantes, CNRS, INSERM, Centre de Recherche en Cancérologie et Immunologie Nantes-Angers, 44000 Nantes, France.
Laboratoire d'Excellence Immunotherapy Graft Oncology, 44000 Nantes, France.
Hematology Biology, Centre Hopitalier-Universitaire, 44000 Nantes, France.

Patrice Chevallier (P)

Université de Nantes, CNRS, INSERM, Centre de Recherche en Cancérologie et Immunologie Nantes-Angers, 44000 Nantes, France.
Laboratoire d'Excellence Immunotherapy Graft Oncology, 44000 Nantes, France.
Hematology Clinic, Centre Hopitalier-Universitaire, 44000 Nantes, France; and.

Christelle Retière (C)

Etablissement Français du Sang, Centre-Pays de la Loire, 44011 Nantes, France; christelle.retiere@efs.sante.fr.
Université de Nantes, CNRS, INSERM, Centre de Recherche en Cancérologie et Immunologie Nantes-Angers, 44000 Nantes, France.
Laboratoire d'Excellence Immunotherapy Graft Oncology, 44000 Nantes, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH